Voyager Therapeutics has chosen a lead development candidate for its superoxide dismutase 1 (SOD1)-mutated amyotrophic lateral sclerosis (ALS) gene therapy programme.
07 Dec 2023
04 Oct 2023
BridgeBio Pharma has entered into a strategic partnership with National Resilience (Resilience) for the manufacturing and advancement of two investigational gene therapies, BBP-812 and BBP-631.
07 Aug 2023
Sage Therapeutics and Biogen have received approval from the US Food and Drug Administration (FDA) for ZURZUVAE (zuranolone) 50 mg to treat postpartum depression (PPD) in adults.
12 Jul 2023
The Australian Therapeutic Goods Administration (TGA) has granted provisional approval to Hansa Biopharma’s Idefirix (imlifidase) as desensitisation treatment for highly sensitised patients before kidney transplantation either from living or deceased donors.
23 Jun 2023
US-based amyloid diseases treatment solutions developer AltPep has raised $52.9m in its Series B investment round led by Senator Investment Group.
29 May 2023
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of Marinus Pharmaceuticals’ ZTALMY (ganaxolone) oral suspension.
04 May 2023
Denmark-based biotech firm Tetra Pharm Technologies has introduced its first product in Germany.
10 Mar 2023
Clinical-stage biotechnology company QurAlis has closed $88m in oversubscribed Series B financing round to advance precision medicines for neurodegenerative diseases.
03 Mar 2023
Avenue Therapeutics has signed an exclusive license agreement with Taiwanese clinical-stage drug company AnnJi Pharmaceutical to develop and commercialise the first-in-class clinical asset, AJ201.
16 Feb 2023
Coya Therapeutics has expanded its exclusive global licensing agreement with ARScience Biotherapeutics for low-dose IL-2 subcutaneous administration product candidate COYA 301.